Widening Horizons     

Published: October 31, 2024
Updated: October 31, 2024

Sudarshan Pharma Industries Ltd.

Board approves acquisition of 51% stake in Ishwari Healthcare

Sudarshan Pharma Industries Ltd. (SPIL) (BSE: 543828), a prominent name engaged in the chemical and pharmaceutical business, has announced that its board has approved to acquire 2,09,100 equity-shares of Ishwari Healthcare Private Limited equivalent to 51.00% of the paid up equity share capital of the Company and enter into Share Purchase Agreement. Upon completion of the acquisition, Ishwari Healthcare would become a subsidiary of the Company.

Ishwari Healthcare Private limited is a progressive & innovative Company dedicated to serve world market by providing superior services, user-friendly and state-of-theart healthcare disposables & devices conforming to international standards at competitive prices. Putting technology to the best use combined with the spirit of innovativeness and creativity, Ishwari Healthcare Private limited provides worldclass products to cater the needs of global customers more effectively and efficiently.

The main object of the subsidiary is to manufacture, formulate, process, develop, refine, import, export all kinds of pharmaceuticals, healthcare, ayurvedic and dietary supplement products, amongst other varied products.

Sudarshan Pharma Industries Ltd. (SPIL), has grown into a prominent name in the chemical and pharmaceutical industries. Led by its promoters, Mr. Hemal V. Mehta and Mr. Sachin V. Mehta, who collectively possess over 25 years of industry experience, SPIL has established a strong foundation in specialty chemicals and bulk drugs. Their vision for creating an integrated chemical and pharmaceutical company has fueled the company’s growth and built a reputation for reliability and innovation.

SPIL operates across various sectors in both the pharmaceutical and chemical industries, with a focus on specialty chemicals and intermediates, which find applications in pharmaceuticals, paints, food products, and adhesives. The company has expanded its presence both domestically and internationally, exporting products to the UK, Australia, Uzbekistan, Syria, Oman, Taiwan, and the MENA region.

In addition to its core operations, SPIL engages in contract manufacturing, outsourcing, and supplying generic pharmaceutical formulations to healthcare institutions, governments, NGOs, and hospitals. The company also maintains its own distribution network and sales force, ensuring ethical marketing of its pharmaceutical products across domestic and global markets.

With regular participation in international trade fairs and exhibitions, especially in Europe and the Gulf countries, SPIL continues to strengthen its global footprint. Committed to innovation and value creation, the company strives to become a premier player in the chemical industry, with a longterm vision of ranking among the Fortune 500 companies.